Abstract 106P
Background
PD-1 inhibition as monotherapy following by CTLA-4 inhibition at progression or as upfront double co-inhibition have drastically improved the outcomes of metastatic melanoma. Still many patients develop resistance to both ICIs and relapse soon, having conventional chemotherapy(CC) as the only therapeutic option. The phase II LEAP-004 trial supported that pembrolizumab/lenvatinib could potentially overcome anti-PD-1/anti-CTLA-4 immunotherapy refractoriness.
Methods
In the absence of any prospective study and to evaluate in a real-world context the clinical benefit of LEAP-004-proposed combination, we conducted here a retrospective comparison of pembrolizumab(200mg Q3W)with lenvatinib(at a reduced dose 10mg OD due to its known toxicity)with CC(carboplatin 4AUC and dacarbazine 850mg/m2 Q3W)in this frail population of unmet need who relapsed to both ICIs, either in combinatorial or in sequential setting. Baseline demographics, disease characteristics as well as treatment outcomes(ORR, PFS and OS)and safety profile were recorded.
Results
A total of 84 patients were included in the effectiveness and safety analysis (pembro/lenva, n=39 and CC, n=45). Median age was 67 vs .64 years and males were 33.3% vs .46.7%, respectively. The distribution of metastases was comparable, including 12.8% vs .20% with brain involvement. Most patients had PS<2 (69.9% vs .56.5%),increased LDH (71.8% vs .84.4%), BRAF-wild status (82.1% vs .84.8%) and received>=2 previous therapies (61.5% vs .53.3%). The median follow-up was 18 months. The ORR was 23.1% vs .11.1% (P<0.0001), the median PFS was 4.8 vs. 3.8 months (HR [95%CI]: 0.57 [0.36-0.92]; P=0.017) and the median OS was 14.2 vs .7.8 months (HR [95%CI]: 0.39 [0.22-0.69], P=0.0009), in pembro/lenva and CC arms, respectively. Grade 3-5 treatment-related AEs were documented in 48.7% vs. 75.6% of patients (P=0.034), led to treatment discontinuation in 10.3% vs. 17.8% of cases, respectively.
Conclusions
This is the first comparative study in patients with metastatic melanoma refractory to PD-1/CTLA-4 inhibition and showed significantly better outcomes in cases treated with pembro/lenva versus CC.
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
D. Ziogas: Financial Interests, Personal, Invited Speaker: AstraZeneca, MSD, BMS, Ipsen, Pierre Fabre, Gilead, Amgen; Financial Interests, Personal, Advisory Board: Roche. M. Liontos: Financial Interests, Personal, Advisory Board: Astra Zeneca, GSK, Janssen, MSD, Pfizer, Bayer, Novartis; Financial Interests, Personal, Invited Speaker: Astellas. H. Gogas: Financial Interests, Personal, Advisory Board: MSD, BMS, Pierre Fabre, Sanofi; Financial Interests, Personal, Invited Speaker: MSD, BMS, Novartis, Pierre Fabre, Sanofi; Financial Interests, Personal, Steering Committee Member: Amgen, Replimune; Financial Interests, Institutional, Local PI: Amgen, MSD, BMS, Replimune, Iovance, Bayer; Financial Interests, Institutional, Research Grant: MSD, Pfizer, Lilly, Pierre Fabre, Astra Zeneca. All other authors have declared no conflicts of interest.
Resources from the same session
185P - Characterizing the metabolic reprogramming of mutant ß-catenin in hepatocellular carcinoma
Presenter: Nathalie Wong
Session: Poster Display session
Resources:
Abstract
186P - Unveil and overcome PD(L)1 antibody resistance via functional genomics and clinical derived biopsies
Presenter: BIN XIE
Session: Poster Display session
Resources:
Abstract
187P - Single-cell RNA sequencing elucidates the role of intercommunication between epithelial cells, immune cells, and fibroblasts in high-grade serous ovarian cancer
Presenter: Xiaoting Zhao
Session: Poster Display session
Resources:
Abstract
188P - Single-cell and spatial transcriptomics delineate the microstructure and immune landscape of intrahepatic cholangiocarcinoma in the leading-edge area
Presenter: Zuyin li
Session: Poster Display session
Resources:
Abstract
189P - Image-guided labeling of live cells in tertiary lymphoid structures for single-cell transcriptomics
Presenter: Mengrui Cao
Session: Poster Display session
Resources:
Abstract
190P - Ex vivo modeling of precision immuno-oncology responses in lung cancer
Presenter: Bassel Alsaed
Session: Poster Display session
Resources:
Abstract
191P - Patient-derived 3D-bioprinted tumours as a relevant and innovative tool for immunotherapeutic testing.
Presenter: Kamila Pawlicka
Session: Poster Display session
Resources:
Abstract
192P - A new neuroendocrine model and in vitro effect of melatonin and serotonin on the PD-L1 ligand and its immunomodulatory action
Presenter: Dulce Caraveo Gutiérrez
Session: Poster Display session
Resources:
Abstract
193P - Humanized mice applying CD47; Prkcd; IL2rg triple KO mice exhibit enhanced human immune cell engraftment and reduced GvHD symptoms
Presenter: Seung-Ho Heo
Session: Poster Display session
Resources:
Abstract
194P - The impact of BTK inhibitors on ?d T cell fitness: Lesson for immunotherapy
Presenter: Adam Michalski
Session: Poster Display session
Resources:
Abstract